SARS-CoV-2 antibodies can bind to two viral targets at once
US researchers find that SARS-CoV-2 bivalent antibodies can continue to neutralise Omicron and Omicron lineages.
List view / Grid view
US researchers find that SARS-CoV-2 bivalent antibodies can continue to neutralise Omicron and Omicron lineages.
An experimental HIV vaccine, delivered as increasing doses over several days, led to long-lasting and diverse antibody production in monkeys.
The study is the first in-depth look at links between COVID-19 severity and gene expression in immune cells and may guide future therapies.
The La Jolla Institute for Immunology and Brigham and Women's Hospital will collaborate to develop a pan-coronavirus vaccine.
Researchers suggest patients who develop mild COVID-19 may not be able to fight reinfection very effectively because their CD8+ T cells show signs of exhaustion.
Researchers have shown that factoring in valency to vaccine design can improve the number of antibody binding sites on an antigen.
Scientists denervated the pancreas using surgery or pharmacological agents to protect it from immune-mediated beta cell destruction, preventing the onset of type 1 diabetes.
A new study shows how the Bcl6 protein can regulate T follicular helper cells, presenting a target for autoimmune and infectious diseases.